Clinician's Roundtable ReachMD

Guest: Ina Park, MD



The United States has seen its largest increase in syphilis cases in the past five years. And with increases prevalent in every region, along with a shortage of medication, additional surveillance strategies and importation resources are necessary. Dive in for a discussion on the challenges and strategies to combat the spread of syphilis with Dr. Ina Park, Professor of Family Community Medicine at the University of California San Francisco School of Medicine.

Host: Matt Birnholz, MD

Guest: Donald Kohn, MD



Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles.
This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Henry Rosenberg, MD



Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat malignant hyperthermia emergencies in operating room settings. Join Dr. Charles Turck as he dives deeper into this topic with Dr. Henry Rosenberg, a member of the Board of Directors of the Malignant Hyperthermia Association of the United States.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Melanie Dispenza, MD



The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also in development for allergy treatment. To learn more, join Dr. Charles Turck as he dives deeper into this study and its findings with Dr. Melanie Dispenza, Assistant Professor of Medicine at Johns Hopkins University School of Medicine.

Host: Charles Flexner, MD



Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Prithviraj Bose, MD



Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.